Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: Four case reports

International Journal of Hematology

Volumn 96, Issue 4, 2012, Pages 506-512

  Iioka, Futoshi ^a   Shimomura, Daiki ^a   Ishii, Toru ^a   Maesako, Yoshitomo ^a   Ohgoe, Kazuhiro ^a   Nakamura, Fumihiko ^a   Matsuo, Shuji ^a   Ohno, Hitoshi ^a  

^a TENRI HOSPITAL   (Japan)

Author keywords

ADAMTS13 activity; Anti ADAMTS13 inhibitor; Plasma exchange; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGED; ARTICLE; CASE REPORT; CHOLANGITIS; CLINICAL FEATURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; MALE; PLASMAPHERESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADAM PROTEINS; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

EID: 84868129528     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1162-2     Document Type: Article

References (24)

1. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354:1927-35. (Pubitemid 43872694)
2. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112:11-8.
3. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116:4060-9.
4. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393-7.
5. Howard MA, Williams LA, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Transfusion. 2006;46:154-6. (Pubitemid 43381799)
6. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;141:149-69. (Pubitemid 351406218)
7. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005;106:1932-7. (Pubitemid 41291703)
8. Jasti S, Coyle T, Gentile T, Rosales L, Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher. 2008;23:151-6.
9. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136:451-61. (Pubitemid 46046304)
10. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006;46:1444-52. (Pubitemid 44117975)
11. Yagi H, Ito S, Kato S, Hiura H, Matsumoto M, Fujimura Y. Plasma levels of ADAMTS13 antigen determined with an enzyme immunoassay using a neutralizing monoclonal antibody parallel ADAMTS13 activity levels. Int J Hematol. 2007;85:403-7. (Pubitemid 47457449)
12. McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:1201-8.
13. Boctor FN, Smith JA. Timing of plasma exchange and rituximab for the treatment of thrombotic thrombocytopenic purpura. Am J Clin Pathol. 2006;126:965 (author reply 965-6). (Pubitemid 44901849)
14. Ojeda-Uribe M, Federici L, Wolf M, Coppo P, Veyradier A. Successful long-term rituximab maintenance for a relapsing patient with idiopathic thrombotic thrombocytopenic purpura. Transfusion. 2010;50:733-5.
15. Lalmuanpuii J, Yalamanchili K, Fircanis S, Nelson JC. Hypersensitivity to plasma exchange in a patient with thrombotic thrombocytopenic purpura. J Clin Apher. 2009;24:18-20.
16. Caramazza D, Quintini G, Abbene I, Coco LL, Malato A, Di Trapani R, et al. Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura- haemolytic uraemic syndrome. Blood Transfus. 2010;8:203-10.
17. Bohm M, Betz C, Miesbach W, Krause M, von Auer C, Geiger H, et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol. 2005;129:644-52. (Pubitemid 40825826)
18. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043-9. (Pubitemid 38685342)
19. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746-53.
20. Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924-30. (Pubitemid 350006946)
21. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13-23.
22. Vassilopoulos D. Should we routinely treat patients with autoimmune/ rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Intern Med. 2011;22:572-5.
23. Tun NM, Villani GM. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. J Thromb Thrombolysis. 2012.
24. Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500-11.